Tocilizumab antibody | AbD21338_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti tocilizumab (clone AbD21338_hIgG1) at a concentration of 2 μg/ml in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with human IgG1/kappa, human IgG1/lambda or tocilizumab at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti tocilizumab (clone AbD21338_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu™ fluorogenic peroxidase substrate. Data presented is the mean of three measurements
A microtiter plate was coated over night with Human anti tocilizumab (clone AbD21362, HCA252) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of tocilizumab. Detection was performed using HRP-conjugated Human anti tocilizumab (clone AbD21338_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data presented is the mean of three measurements
A microtitre plate was coated over night with tocilizumab at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of different Human anti tocilizumab clones, AbD21338_hIgG1 (HCA253), AbD21364_hIgG1 (HCA254), AbD21346_hIgG1 (HCA255) and AbD21345_hIgG1 (HCA256). Detection was performed using HRP-conjugated tocilizumab. Data presented is the mean of two measurements. HRP-conjugation of tocilizumab used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®
A microtiter plate was coated over night with human interleukin 6 receptor at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of tocilizumab (0.3 μg/ml) plus increasing concentrations of the monovalent Fab fragment of the inhibitory Human anti tocilizumab clone AbD21338_hIgG (HCA253) or the non-inhibitory clone AbD22155_hIgG1 (HCA257) was added. Free tocilizumab, still capable of binding to the human interleukin 6 receptor-coated plate, was detected using Mouse anti Human IgG (Fc) CH2 Domain:HRP (MCA647P) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements
Human anti Tocilizumab:HRP
Anti-tocilizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for tocilizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
Human anti Tocilizumab
Anti-tocilizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for tocilizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
- Product Type
- Monoclonal Antibody
- Clone
- AbD21338_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA253P | E | 0.1 mg |
|
|
| HCA253 | E | 0.1 mg |
|
|
| HCA253G | E | 1 mg |
|
Human Anti-Tocilizumab Antibody, clone AbD21338 is a paratope specific, anti-idiotypic antibody that binds to free tocilizumab but not to human Interleukin-6 Receptor (IL-6R) or the drug/IL-6R complex. The antibody can be used to measure the levels of tocilizumab and biosimilar products in bioanalytical and patient monitoring assays.
Clone AbD21338_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator (high affinity) in an anti-drug antibody (ADA) assay. Additionally it can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Tocilizumab Antibody clone AbD21362 (HCA252) in monovalent Fab format as the capture antibody.
Tocilizumab (RoActemra/Actemra) is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody is directed against IL-6R and acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine.
View a summary of all anti-tocilizumab antibodies
Clone AbD21338_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator (high affinity) in an anti-drug antibody (ADA) assay. Additionally it can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Tocilizumab Antibody clone AbD21362 (HCA252) in monovalent Fab format as the capture antibody.
Tocilizumab (RoActemra/Actemra) is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody is directed against IL-6R and acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine.
View a summary of all anti-tocilizumab antibodies
Product Details
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Tocilizumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=0.1 nM by real time, label-free molecular interaction analysis on immobilized tocilizuimab.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Pack Size: 0.1 mgAntibody concentration 0.5 mg/mlPack Size: 1 mgAntibody concentration 1.0 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Actemra® and RoActemra® are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd. - Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Actemra® and RoActemra® are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Tocilizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA252 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA252 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
This antibody is fully human and can be used as a reference standard in an ADA assay.
Protocol: ADA bridging ELISA
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Tocilizumab | HCA252 | E* | 0.1 mg |
|
|
| Human anti Tocilizumab | HCA254 | E | 0.1 mg |
|
|
| Human anti Tocilizumab | HCA255 | E | 0.1 mg |
|
|
| Human anti Tocilizumab | HCA256 | E | 0.1 mg |
|
|
| Human anti Tocilizumab | HCA257 | E | 0.1 mg |
|
|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Tocilizumab | HCA252 | E* | 0.1 mg |
|
|
| Human anti Tocilizumab | HCA254 | E | 0.1 mg |
|
|
| Human anti Tocilizumab | HCA255 | E | 0.1 mg |
|
|
| Human anti Tocilizumab | HCA256 | E | 0.1 mg |
|
|
| Human anti Tocilizumab | HCA257 | E | 0.1 mg |
|
|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | ||
| Mouse anti Human IgG (Fc) CH2 Domain:HRP | MCA647P | C* E | 0.2 mg |
|
